|
| |
kadmus kds-4103 Pages on BioPortfolio:
Results from other life science and pharmaceutical sites:
Non-linear enzymatic logic in natural product modular mega ...
based on the development of KDS-4103 and any other. follow-on compounds. KDS- 4103, which was originally. licensed to Kadmus from the University of ...
http://www.biomedcentral.com/content/pdf/cd-827283.pdf...
|
BioPortfolio - Kadmus Pharmaceuticals
Recent Publications by Kadmus Pharmaceuticals:. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). In the present article, ...
http://www.bioportfolio.com/biocorporate/5988-Kadmus_Pharmac...
|
The endocannabinoid system: A drug discovery perspective Daniele ...
such as URB-597 (11, KDS-4103; Kadmus Pharmaceuticals. Inc; Figure 7) which was invented and patented jointly by. the Universities of California, ...
http://www.biomedcentral.com/content/pdf/cd-608185.pdf...
|
Pharmacological profile of the selective FAAH inhi...[CNS Drug Rev ...
Kadmus Pharmaceuticals, Inc. Irvine, California 92697-4625, USA. piomelli@uci. edu ... In vitro, KDS-4103 inhibits FAAH activity with median inhibitory ...
http://www.ncbi.nlm.nih.gov/pubmed/16834756...
|
Enhancement of endocannabinoid signaling and the pharmacotherapy ...
Dr. Piomeli is a co-founder of, and consultant for Kadmus Pharmaceuticals, Inc., which is currently developing URB597 (KDS-4103). ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=21...
|
|
